Meet us at the Biotechgate Digital Partnering event 2020
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Proteona will take part in the Biotechgate virtual business development event, taking place from the 31st of August to the 3rd of September.
Biotechgate is an international database for biotech and Pharma business development. For this event, Biotechgate offers its digital partnering platform for free to support Life Science companies in response to COVID-19. More than 1000 delegates from biotech, medtech, and pharmaceutical companies will participate in the event.
Dr Andreas Schmidt, the CEO of Proteona, will be available during the event for further discussion.
Schedule a meeting now with Proteona through the conference networking platform!
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).